Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.82 |
| ▸ | PDE2A | O00408 | 1/20 | 0.82 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.82 |
| ▸ | PDE6D | O43924 | 1/20 | 0.82 |
| ▸ | PDE8A | O60658 | 1/20 | 0.82 |
| ▸ | PDE9A | O76083 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | PDE6A | P16499 | 1/20 | 0.82 |
| ▸ | PDE6G | P18545 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PDE6B | P35913 | 1/20 | 0.82 |
| ▸ | PDE6C | P51160 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL33982 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6509338 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405882 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL29424508 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL28791531 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL27980438 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6685385 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL19410963 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL17101160 | 0.99 | PDE5A (0.97) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL7374712 | 0.98 | PDE5A (0.96) | PDE5AABCC4PDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042927-A1 | PHOSPHODIESTERASE INHIBITORS TO REPAIR BRAIN AND/OR RETINAL INJURY IN HUMAN NEWBORNS | WINTERMARK PIA (CA) | 2018-02-15 | — | — | US | disclosed |
| WO-2015134695-A1 | METHOD OF MITIGATING THE SIDE EFFECTS OF A PHOSPHODIESTERASE TYPE V INHIBITOR IN A SUBJECT | VYRIX PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20130338166-A1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2114147-B9 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2486927-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2486921-A1 | Reducing Side Effects of Tramadol | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2114147-B1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2120570-B1 | TREATMENT OF COMORBID PREMATURE EJACULATION AND ERECTILE DYSFUNCTION | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120018345-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| US-20120018333-A1 | Reducing Side Effects of Tramadol | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| EP-1301619-A4 | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS | TRANSFORM PHARMACEUTICALS INC (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004040006-A1 | TRANSDERMAL ASSAY WITH MAGNETIC CLAMP | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1204766-A4 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1301619-A1 | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS | Transform Pharmaceuticals, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1248869-A2 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | Transform Pharmaceuticals, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1204766-A1 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | Transform Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001051919-A9 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS INC (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002006518-A1 | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001051919-A2 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001009391-A1 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |